Erratum: IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (Diabetologia (2005) 48 (703-708) DOI: http://dx.doi.org/10.1007/s00125-005-1691-9);IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)

Diabetologia

Volumn 48, Issue 4, 2005, Pages 703-708

  Bottazzo, G F ^a   Bosi, E ^b   Cull, C A ^c   Bonifacio, E ^b   Locatelli, M ^a   Zimmet, P ^d   MacKay, I R ^e   Holman, R R ^c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

GADA; IA2A; ICA; Insulin requirement; Islet cell autoantibodies; Type 2 diabetes; UKPDS

Indexed keywords

AUTOANTIGEN; GLUTAMATE DECARBOXYLASE ANTIBODY; IA ANTIBODY; INSULIN; ISOENZYME; METFORMIN; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT ANTIGEN; SULFONYLUREA;

ADULT; AGED; ALLELE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VALIDATION PROCESS;

EID: 17844403542     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1808-1     Document Type: Erratum

References (23)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362
2. World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a WHO Consultation Part 1: Diagnosis and Classification of Diabetes Mellitus
3. Atkinson M, Eisenbarth G (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229
4. UKPDS Group (1997) UKPDS 25: Clinical value of ICA and GADA in predicting insulin requirement in patients with newly diagnosed NIDDM at different ages. Lancet 350:1288-1293
5. Tuomi T, Carlsson A, Isomaa B et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150-157
6. Vardi P, Ziegler AG, Mathews JH et al (1988) Concentration of insulin autoantibodies at onset of type 1 diabetes. Inverse log-linear correlation with age. Diabetes Care 11:736-739
7. Notkins A, Lan M, Leslie R (1998) IA-2 and IA-2beta: the immune response in IDDM. Diabetes/Metab Rev 14:85-93
8. UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877-890
9. Bonifacio E, Lampaspona V, Genovese S, Ferrari M, Bosi E (1995) Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a component of islet cell antibodies. J Immunol 155:5419-5426
10. Bonifacio E, Lampaspona V, Bingley PJ (1998) IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphate autoantigens. J Immunol 161:2648-2654
11. Bingley PJ, Bonifacio E, Mueller P (2003) Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 52:1128-1136
12. Bonifacio E, Bingley PJ, Shattock M et al (1990) Quantification of islet-cell antibodies and prediction of insulin dependent diabetes. Lancet 335:147-149
13. Verge CF, Stenger D, Bonifacio E et al (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 47:1857-1866
14. UKPDS Group (1994) UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
16. Levy J, Matthews D, Hermans M (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
17. UKPDS Group (1999) UKPDS 43. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes. Diabetologia 42:608-616
18. Genovese S, Bonfanti R, Bazzigaluppi E et al (1996) Association of IA2 antibodies with HLA DR4 phenotype in insulin dependent diabetes. Diabetologia 39:1223-1226
19. Davis TME, Wright AD, Mehta ZM et al (2004) Islet cell autoantibodies in type 2 diabetes: prevalence and relationship with metabolic control. Diabetologia DOI 10.1007/s00125-005-1690-x
20. Mire-Sluis AR, Gaines Das R, Lermark A (2000) The world health organization international collaborative study for islet cell antibodies. Diabetologia 43:1282-1292
21. Zimmet PZ (1999) Diabetes epidemiology as a trigger to diabetes research. Diabetologia 42:499-518
22. Wiltshire S, Hattersley A, Hitman G et al (2001) A genome-wide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigree provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 69:553-569
23. UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853